Učitavanje...
CD19-CAR Trials
CD19 is a B-lineage specific transmembrane glycoprotein, the expression of which is maintained on more than 95% B-cell malignancies. This strict lineage restriction makes CD19 an ideal target for immune therapies using chimeric antigen receptors (CARs). Here we review published phase I trials of T c...
Spremljeno u:
| Glavni autori: | , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2014
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3979594/ https://ncbi.nlm.nih.gov/pubmed/24667955 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/PPO.0000000000000031 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|